PT-141 and oxytocin belong to different signaling families. The original overview of this page asks readers to begin a comparison with receptor targets, to keep sequence and sample handling distinct, and to design non-clinical comparison studies without conflating endpoints.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not a ranking, not claims about a Velnacor lot, and not instructions for use in people or animals.
Melanocortin signaling compared with oxytocin-receptor signaling
Molinoff and colleagues described PT-141 as a synthetic peptide analogue of α-melanocyte-stimulating hormone (α-MSH) and as an agonist at melanocortin receptors, including MC3R and MC4R, which are expressed primarily in the central nervous system (Molinoff et al., 2003). Diamond and colleagues later described PT-141 as a cyclic heptapeptide melanocortin analogue (Diamond et al., 2004). A PT-141 identity note is at What Is PT-141?.
Oxytocin is a different peptide. Gimpl and Fahrenholz reviewed the oxytocin receptor as a G-protein-coupled receptor for the neurohypophysial peptide oxytocin, and they summarized the structure, function, and regulation of that receptor system, including hypothalamic expression and stimulus-dependent release from the posterior pituitary (Gimpl and Fahrenholz, 2001). An oxytocin-receptor assay does not document a melanocortin agonist, and a melanocortin-receptor assay does not document oxytocin.
| Name | What the cited literature identifies | What not to assume |
|---|---|---|
| PT-141 | A cyclic melanocortin analogue and MC3R/MC4R agonist, also known as bremelanotide (Molinoff et al., 2003; Diamond et al., 2004). | That erectile-response findings in those papers document oxytocin. |
| Oxytocin | A neurohypophysial peptide whose receptor system is reviewed by Gimpl and Fahrenholz (Gimpl and Fahrenholz, 2001). | That a shared catalog category or shipping carton merges receptor families. |
Published observations, and why endpoints should not be conflated
Molinoff and colleagues reported that administration of PT-141 to rats and nonhuman primates resulted in penile erections, that systemic administration to rats increased hypothalamic c-Fos immunoreactivity, and that administration in the human study populations they described was associated with an increase in erectile activity (Molinoff et al., 2003). Diamond and colleagues reported that, in healthy men and in men with erectile dysfunction in a double-blind, placebo-controlled design, an erectile response measured by RigiScan was statistically significant versus placebo in the dose groups they identified (Diamond et al., 2004). Those papers are published pharmacology and early clinical-research findings for PT-141. They are not oxytocin results, they are not a protocol, and they do not provide administration guidance.
Citation flag. A single peer-reviewed study that compared PT-141 and oxytocin head-to-head in one experimental design was not verified for this draft. The comparison is a documentation framework built from receptor-identity literature. It is not a pooled efficacy table.
Sequence, handling, and separate lot files
Sequence, cyclic versus linear form, and sample handling should be written per material. Matched analytical controls do not make the two peptides interchangeable. How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, lot traceability, and How to Evaluate a Peptide Supplier: B2B Checklist apply independently to each line item.
Catalog records exist for PT-141 (slug pt141) and oxytocin. There is not a standalone public landing page for every name; use the product directory and the COA Library, then confirm each SKU in the inquiry. For packing at supply scale, see wholesale peptides.
Selected published literature
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x. PubMed 12851303. Cited as published pharmacology and early clinical-research observations, not as a use instruction.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1):51-59. doi:10.1038/sj.ijir.3901139. PubMed 14963471. Cited as published clinical-research observations, not as a use instruction.
- Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews. 2001;81(2):629-683. doi:10.1152/physrev.2001.81.2.629. PubMed 11274341. Review article; cited for oxytocin-receptor identity.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.